These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38164032)

  • 1. The Long-Term Impact of 5-alpha Reductase Inhibitors on the Development of Bladder Cancer and the Need for Radical Cystectomy: A Nationwide Observational Study.
    Pyun JH; Son NH; Ko YH; Kim SW; Kim H; Bae YJ
    World J Mens Health; 2024 Apr; 42(2):460-466. PubMed ID: 38164032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5α-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort.
    Dekalo S; McArthur E; Campbell J; Ordon M; Power N; Welk B
    Urol Oncol; 2023 Jan; 41(1):50.e11-50.e17. PubMed ID: 36319553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.
    Preston MA; Wilson KM; Markt SC; Ge R; Morash C; Stampfer MJ; Loda M; Giovannucci E; Mucci LA; Olumi AF
    JAMA Intern Med; 2014 Aug; 174(8):1301-7. PubMed ID: 24887392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of 5α-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea.
    An MH; Kim MS; Kim C; Noh TI; Joo KJ; Lee DH; Yi KH; Kwak JW; Hwang TH; Park RW; Kang SH
    JAMA Netw Open; 2023 May; 6(5):e2313667. PubMed ID: 37191958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term use of 5-alpha-reductase inhibitors is safe and effective in men on active surveillance for prostate cancer.
    Finelli A; Komisarenko M; Martin LJ; Timilshina N; Jain K; Morris J; Zlotta A; Kulkarni G; Perlis N; van der Kwast T; Evans A; Ghai S; Fleshner N; Alibhai SMH; Hamilton RJ
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):69-76. PubMed ID: 32152437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
    Ayodele O; Cabral HJ; McManus D; Jick S
    Clin Epidemiol; 2021; 13():661-673. PubMed ID: 34377032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Use of 5-Alpha Reductase Inhibitors and Alpha-1 Blockers Does Not Improve Clinical Outcome in Male Patients Undergoing Radical Cystectomy for Bladder Cancer in Quebec, Canada.
    Wissing MD; O'Flaherty A; Dragomir A; Tanguay S; Kassouf W; Aprikian AG
    Clin Genitourin Cancer; 2021 Aug; 19(4):371-371.e9. PubMed ID: 33676834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship.
    Hensley PJ; Duan Z; Bree K; Sood A; Zhao H; Lobo N; Contieri R; Campbell MT; Guo CC; Navai N; Williams SB; Dinney CP; Kamat AM
    Urol Oncol; 2023 Feb; 41(2):108.e11-108.e17. PubMed ID: 36404232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
    Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
    BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of rhabdomyolysis from 5-α reductase inhibitors.
    Welk B; McArthur E; Ordon M; Dirk J; Dixon S; Garg AX
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):351-355. PubMed ID: 29368380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short- and long-term survival has improved after radical cystectomy for bladder cancer in Québec during the years 2000-2015.
    Wissing MD; Santos F; Zakaria AS; O'Flaherty A; Tanguay S; Kassouf W; Aprikian AG
    J Surg Oncol; 2019 Jun; 119(8):1135-1144. PubMed ID: 30919984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy.
    Heo JE; Koo KC; Hong SJ; Park SU; Chung BH; Lee KS
    Yonsei Med J; 2018 Mar; 59(2):219-225. PubMed ID: 29436189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.
    Turker P; Bostrom PJ; Wroclawski ML; van Rhijn B; Kortekangas H; Kuk C; Mirtti T; Fleshner NE; Jewett MA; Finelli A; Kwast TV; Evans A; Sweet J; Laato M; Zlotta AR
    BJU Int; 2012 Sep; 110(6):804-11. PubMed ID: 22321341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations.
    Earnshaw SR; McDade CL; Black LK; Bell CF; Kattan MW
    Pharmacoeconomics; 2010; 28(6):489-505. PubMed ID: 20196623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
    Issa MM; Runken MC; Grogg AL; Shah MB
    Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
    Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
    Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5α-Reductase Inhibitors Are Associated with Reduced Risk of SARS-CoV-2 Infection: A Matched-Pair, Registry-Based Analysis.
    Lyon M; Li J; Cullen J; Milinovich A; Kattan M; Jehi L; Sharifi N; Klein EA
    J Urol; 2022 Jan; 207(1):183-189. PubMed ID: 34433301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Safety and Possible Benefit of a 5-Alpha Reductase Inhibitor among Benign Prostatic Hyperplasia Patients, A Nationally Representative Cohort of Korean Men.
    Chang J; Choi S; Kim K; Park SM
    J Clin Med; 2019 May; 8(5):. PubMed ID: 31121994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of chronic exposure to 5-alpha reductase inhibitors on the risk of hospitalization for COVID-19: a case-control study in male population from two COVID-19 regional centers of Lombardy, Italy.
    Lazzeri M; Duga S; Azzolini E; Fasulo V; Buffi N; Saita A; Lughezzani G; Paraboschi EM; Hurle R; Nobili A; Cecconi M; Guazzoni G; Casale P; Asselta R;
    Minerva Urol Nephrol; 2022 Feb; 74(1):77-84. PubMed ID: 33439572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.